Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Antibody drug conjugates (ADCs) are poised to become an important class of cancer therapeutics, as evidenced by the promising objective response rates when administered as single agents to chemorefractory cancer patients.
Currently, approximately 60 ADCs are being developed in oncology. Among them, about 20 are undergoing clinical testing, the majority of which are tubulin inhibitor-based immunoconjugates.
…